Prolyl hydroxylase domain 2 protein is a strong prognostic marker in human gastric cancer

Pathobiology

Volumn 79, Issue 1, 2012, Pages 11-17

  Kamphues, Carsten ^a   Wittschieber, Daniel ^a   Klauschen, Frederick ^a   Kasajima, Atsuko ^a   Dietel, Manfred ^a   Schmidt, Sven Christian ^a   Glanemann, Matthias ^a   Bahra, Marcus ^a   Neuhaus, Peter ^a   Weichert, Wilko ^b   Stenzinger, Albrecht ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Angiogenesis; EGL nine homolog 1; Gastric cancer; Hypoxia inducible factor; Prolyl hydroxylase domain 2 protein

Indexed keywords

BIOLOGICAL MARKER; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLYL HYDROXYLASE DOMAIN 2 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CYTOPLASM; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STOMACH ADENOCARCINOMA; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; PROCOLLAGEN-PROLINE DIOXYGENASE; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84855882979     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000330170     Document Type: Article

References (29)

1. Kobayashi T, Kikuchi S, Lin Y, Yagyu K Obata Y, Ogihara A, et al: Trends in the inci-dence of gastric cancer in Japan and the as-sociations with Helicobacter pylori infection and gastric mucosal atrophy. Gastric Cancer 2004; 7: 233-239.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Mur-ray T, et al: Cancer statistics, 2008. CA Can-cer J Clin 2008; 58: 71-96.
3. Alberts SR, Cervantes A, van de Velde CJ: Gastric Cancer: epidemiology, pathology and treatment. Ann Oncol 2003; 14: 2:31-36.
4. Shi Y, Zhou Y: The role of surgery in the treatment of gastric cancer. J Surg Oncol 2010; 101:687-692.
5. D'souza MA, Singh K, Shrikhande SV: Sur-gery for gastric cancer: an evidence-based perspective. J Can Res Ther 2009; 5:225-231.
6. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al: D2 lymph-adenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008; 359:453-462.
7. Strong VE, Devaud N, Allen PJ, Gonen M, Brennan MF, Coit D: Laparoscopic versus open subtotal gastrectomy for adenocarci-noma: a case-control study. Ann Surg Oncol 2009; 16:1507-1513.
8. Fong GH, Takeda K: Role and regulation of prolyl hydroxylase domain proteins. Cell Death Differ 2008; 15:635-641. (Pubitemid 351405066)
9. Bruick RK, McKnight SL: A conserved fam-ily of prolyl-4-hydroxylases that modify HIF. Science 2001; 294:1337-1340. (Pubitemid 33063099)
10. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J: HIF prolyl-hydroxy-lase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J 2003; 22:4082-4090. (Pubitemid 37021737)
11. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al: Overexpres-sion of hypoxia-inducible factor 1α in com-mon human cancers and their metastases. Cancer Res 1999; 59: 5830-5835.
12. Semenza GL: HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002; 8: 62-67.
13. Carmeliet P, Jain RK: Angiogenesis in cancer and other disease. Nature 2000; 407:249-257.
14. Semenza GL: Targeting HIF-1 for cancer therapy. Nature 2003; 3:721-731.
15. Lee KA, Lynd JD, O'Reilly S, Kiupel M, Mc-Cormick JJ, LaPres JJ: The biphasic role of the hypoxia-inducible factor prolyl-4-hy-droxylase, PHD2, in modulating tumor-forming potential. Mol Cancer Res 2008; 6: 829-842.
16. Kato H, Inoue T, Asanoma K, Nishimura C, Matsuda T, Wake N: Induction of human en-dometrial cancer cell senescence through modulation of HIF-1α activity by EGLN1. Int J Cancer 2006; 118:1144-1153. (Pubitemid 43185600)
17. Chan DA, Kawahara TL, Sutphin PD, Chang HY, Chi JT, Giaccia AJ: Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 2009; 15: 527-538.
18. Chan DA, Giaccia AJ: PHD2 in tumor angio-genesis. Br J Cancer 2010; 1:1-5.
19. Vogel S, Wottawa M, Farhat K, Zieseniss A, Schnelle M, Lee-Huu S, et al: Prolyl hydroxy-lase domain (PHD) 2 affects cell migration and F-actin formation RhoA/rho-associated kinase-dependent cofilin phosphorylation. J Biol Chem 2010; 285:33756-33763.
20. Jokilehto T, Rantanen K, Luukkaa M, Heik-kinen P, Grenman R, Minn H, et al: Overex-pression and nuclear translocation of hypox-ia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness. Clin Cancer Res 2006; 12:1080-1087. (Pubitemid 43342495)
21. Weichert W, Röske A, Gekeler V, Beckers T, Ebert MP, Pross M, et al: Association of pat-terns of class I histone deacetylase expres-sion with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008; 9: 139-148.
22. Weichert W, Ullrich A, Schmidt M, Gekeler V, Noske A, Niesporek S, et al: Expression patterns of polo-like kinase 1 in human gas-tric cancer. Cancer Sci 2006; 97:271-276.
23. Jain RK: A New Target for Tumor Therapy. N Engl J Med 2009; 360: 269-271.
24. Durczak M, Jagodzinski PP: Apicidin upreg-ulates PHD2 prolyl hydroxylase gene expres-sion in cervical cancer cells. Anti Cancer Drugs 2010; 21:619-624.
25. Choi HJ, Song BJ, Gong YD, Gwak WJ, Soh Y: Rapid degradation of hypoxia-inducible factor-1α by KRH102053, a new activator of prolyl hydroxylase 2. Br J Pharmacol 2008; 154:114-125. (Pubitemid 351620399)
26. Spinella F, Rosano L, Di Castro V, Decandia S, Nicotra MR, Natali PG, et al: Endothelin-1 and endothelin-3 promote invasive behav-iour via hypoxia-inducible factor-1α in hu-man melanoma cells. Cancer Res 2007; 67: 1725-1734. (Pubitemid 46383399)
27. Spinella F, Rosano L, Del Duca M, Di Castro V, Nicotra MR, Natali PG, et al: Endothelin-1 inhibits prolyl hydroxylase domain 2 to acti-vate hypoxia-inducible factor-1α in melano-ma cells. PLoS 2010; 5:e11241.
28. Brökers N, Le-Huu S, Vogel S, Hagos Y Katschinski DM, Kleinschmidt M: Increased chemoresistance induced by inhibition of HIF-prolyl-hydroxylase domain enzymes. Cancer Sci 2010; 101:129-136.
29. Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, Jonckx B, et al: Hetero-zygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via en-dothelial normalization. Cell 2009; 136: 839-851.